Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Rectal Neoplasms 2Colonic Neoplasms 2Breast Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Melanoma 1Lung Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Cardiotoxicity 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Adenocarcinoma Of Esophagus 1

Interventions

Cyclophosphamide 18Trastuzumab 16Paclitaxel 15Taxes 11Doxorubicin 11Radiotherapy 7Lapatinib 6Albumin-Bound Paclitaxel 6Vorinostat 5Tamoxifen 5Docetaxel 5Carboplatin 5Capecitabine 5Bevacizumab 5Radiation 4Letrozole 4Immunohistochemistry 4Anastrozole 4sargramostim 3pegfilgrastim 3exemestane 3Magnetic Resonance Spectroscopy 3Immunoenzyme Techniques 3Granulocyte-Macrophage Colony-Stimulating Factor 3Granulocyte Colony-Stimulating Factor 3Fluorodeoxyglucose F18 3Flow Cytometry 3Filgrastim 3Chemotherapy, Adjuvant 3saponin QA-21V1 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Breast Neoplasms, Male × Mass Spectrometry × Clear all
NCT00436566 2022-08-05

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Mayo Clinic

Phase 2 Completed
122 enrolled 22 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡